Skip to main content

Jacobson Mark L.'s Form 4 filing

Axsome Therapeutics, Inc. (AXSM) · filed Sep 3, 2026

Accession no.
0001193125-26-382277
Filed
Sep 3, 2026, 7:09 PM ET
Trade date
Sep 3, 2026
Filing delay
Same day
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.09M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Jacobson Mark L.CIK 0001805812Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 3, 2026Common StockMOption exerciseAcquired+10,000$12.95+$129,50010,000Direct
Sep 3, 2026Common StockSSaleDisposed−10,000$208.65F4−$2,086,5000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 3, 2026Common StockMOption exerciseDisposed−10,000$0.00$0104,954Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F4

Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $206.41 and $210.34.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)